Leukemia Research
Volume 30, Issue 12 , Pages 1581-1583 , December 2006

Successful treatment of multi-agent chemotherapy with rituximab for IgM plasma cell leukemia

  • Satoko Oka

      Affiliations

    • First Department of Internal Medicine, Osaka Medical College, 2-7 Daigakumachi, Takatsuki City, Osaka 569-0801, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 72 683 1221; fax: +81 72 684 6531.
    • ,
  • Taiji Yokote

      Affiliations

    • First Department of Internal Medicine, Osaka Medical College, 2-7 Daigakumachi, Takatsuki City, Osaka 569-0801, Japan
    • ,
  • Toshikazu Akioka

      Affiliations

    • First Department of Internal Medicine, Osaka Medical College, 2-7 Daigakumachi, Takatsuki City, Osaka 569-0801, Japan
    • ,
  • Satoshi Hara

      Affiliations

    • First Department of Internal Medicine, Osaka Medical College, 2-7 Daigakumachi, Takatsuki City, Osaka 569-0801, Japan
    • ,
  • Takeshi Yamano

      Affiliations

    • First Department of Internal Medicine, Osaka Medical College, 2-7 Daigakumachi, Takatsuki City, Osaka 569-0801, Japan
    • ,
  • Motomu Tsuji

      Affiliations

    • Division of Surgical Pathology, Osaka Medical College, 2-7 Daigakumachi, Takatsuki City, Osaka 569-0801, Japan
    • ,
  • Toshiaki Hanafusa

      Affiliations

    • First Department of Internal Medicine, Osaka Medical College, 2-7 Daigakumachi, Takatsuki City, Osaka 569-0801, Japan

Received 20 January 2006 ,Revised 1 February 2006 ,Accepted 1 February 2006.

References 

  1. Pruzanski W, Platts ME, Ogryzlo MA. Leukemic form of immunocytic dyscrasia (plasma cell leukemia). A study of ten cases and a review of the literature. Am J Med. 1969;47:60–74
  2. Kosmo MA, Gale RP. Plasma cell leukemia with IgA paraproteinemia and hyperviscosity. Am J Hematol. 1988;28(June (2)):113–115
  3. Dimopoulos MA, Palumbo A, Delasalle KB, Alexanian R. Primary plasma cell leukemia. Br J Haematol. 1994;88:754–759
  4. Hovvenga S, de Wolf JT, Klip H, Vellenga E. Consolidation therapy with autologous stem cell transplantation in plasma cell leukemia after VAD, high-dose cyclophosphamide and EDAP courses: a report of three cases and review of the literature. Bone Marrow Transplant. 1997;20:901–904
  5. Costello R, Sainty D, Bouabdallah R, Fermand JP, Delmer A, Divine M, et al. Primary plasma cell leukaemia: a report of 18 cases. Leuk Res. 2001;25(February (2)):103–107
  6. Malhotra H, Dhabhar BN, Saikia TK, et al. Ifosfamide in plasma cell leukaemia. Am J Hematol. 1992;40:226–228
  7. Morel P, Monconduit M, Jacomy D, Lenain P, Grosbois B, Bateli C, et al. Prognostic factors in Waldenström's macroglobulinaemia: a report on 232 patients with the description of a new scoring system and its validation on 253 other patients. Blood. 2000;96:852–858
  8. Garcia-Sanz R, Orfao A, Gonzalez M, Tabernero MD, Blade J, Moro MJ, et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood. 1999;93(February (3)):1032–1037
  9. Campbell P, Marcus R. Monoclonal antibody therapy for lymphoma. Blood. 2003;17:143–152
  10. Dimopoulos MA, Zervas C, Zomas A, Kiamouris C, Viniou NA, Grigoraki V, et al. Treatment of Waldenstrom's macroglobulinemia with rituximab. J Clin Oncol. 2002;20:2327–2333
  11. Ghobrial IM, Gertz MA, Fonseca R. Waldenstrom macroglobulinaemia. Lancet Oncol. 2003;4:679–685
  12. Dimopoulus M, Alexanian R, Gika D, Anagnostpoulos A, Zervas C, Zomas A, et al. Treatment of Waldenström's macroglobulinaemia with rituximab: prognostic factors for response and progression. Leuk Lymphoma. 2004;45:2057–2061
  13. Mori A, Tamaru J, Kondo H. Effects of rituximab on a patient with Waldenstrom's macroglobulinaemia with deletion 13q14. Eur J Haematol. 2002;69:321–323
  14. Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, LoBuglio AF, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 1999;17:268–276
  15. Kewalramani T, Zelenetz AD, Nimer SD, Portlock C, Straus D, Noy A, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2004;103:3684–3688
  16. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting—Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835–3849
  17. Harris NL, Jaffe ES, Stein H, et al. A revised European American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;82:3148–3150

PII: S0145-2126(06)00056-7

doi: 10.1016/j.leukres.2006.02.012

Leukemia Research
Volume 30, Issue 12 , Pages 1581-1583 , December 2006

Article Tools

* Image Usage & Resolution